Semaglutide + B12
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Semaglutide with B12 is a compounded GLP-1 weight-management formulation. It pairs semaglutide — a GLP-1 receptor agonist studied extensively for blood-sugar control and weight loss — with vitamin B12 (cyanocobalamin), and in some products glycine, in a single injectable preparation.
Semaglutide itself is FDA-approved and sold under brand names including Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management). The compounded semaglutide-plus-B12 version, however, is prepared by compounding pharmacies and is not FDA-approved. The FDA does not review compounded products for safety, effectiveness, or quality.
These formulations are widely offered through US compounding pharmacies and telehealth clinics, where the added B12 and glycine are commonly marketed to support energy and to offset the fatigue some people report while on GLP-1 therapy. Whether the additives contribute meaningfully to that goal has not been established.
How it works
Semaglutide mimics the hormone GLP-1, which the gut releases after eating. By activating GLP-1 receptors in the brain, pancreas, and digestive tract, it is understood to reduce appetite, promote a feeling of fullness, and slow gastric emptying — effects studied for their role in reducing food intake and body weight. In clinical trials of once-weekly semaglutide, participants lost substantially more weight than those on placebo.
The added vitamin B12 (cyanocobalamin) plays a role in normal energy metabolism and nerve function. It is included as a nutritional additive rather than as a driver of weight loss, and glycine, when present, is an amino acid marketed for similar supportive framing. The specific benefit of these additives within the combination has not been established in controlled studies.
Reported benefits
- Appetite reduction and increased fullness (from the semaglutide component; supported by clinical trials of branded semaglutide)
- Meaningful weight loss when paired with lifestyle changes (studied for branded semaglutide)
- B12 and glycine marketed to support energy and reduce GLP-1-associated fatigue (not established)
These are reported and marketed effects; the weight-loss evidence applies to semaglutide itself, not specifically to the compounded B12 combination.
Considerations & side effects
The most commonly reported side effects reflect the GLP-1 component and include nausea, vomiting, diarrhea, constipation, and abdominal discomfort, which often ease over time. Less common but more serious risks reported with semaglutide include pancreatitis, gallbladder problems, and kidney issues, often linked to dehydration from GLP-1 side effects.
Because the compounded combination is not FDA-approved, its potency, purity, and the effect of the added ingredients are not independently verified, and product quality can vary between pharmacies. Regulators have flagged dosing errors and adverse events associated with compounded semaglutide. This information is educational and is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is compounded semaglutide with B12?
It is a compounded weight-management formulation that combines semaglutide — a GLP-1 receptor agonist — with vitamin B12 (cyanocobalamin), and sometimes glycine, in a single injection. It is prepared by compounding pharmacies rather than a branded manufacturer.
Is semaglutide with B12 FDA-approved?
No. While semaglutide itself is FDA-approved under brand names such as Ozempic, Wegovy, and Rybelsus, this specific compounded combination with B12 is not FDA-approved and is not evaluated by the FDA for safety, effectiveness, or quality.
Why is B12 added to the semaglutide?
Compounders commonly add B12 (and glycine) marketed to support energy and to help offset the fatigue some people report on GLP-1 therapy. The safety and effectiveness of combining semaglutide with these added ingredients has not been established.
Does the B12 make it work better for weight loss?
There is no established evidence that adding B12 improves the weight-loss effect of semaglutide. The weight-management effect is attributed to the semaglutide (GLP-1) component; B12 is included as a nutritional additive.
References
Related compounds
Weight blend combining the amylin analog cagrilintide with the GIP/GLP-1 dual agonist tirzepatide, targeting satiety and glycemic pathways together. No human trial of this exact combination; research-level, sold pre-blended.
Dual-mechanism weight blend pairing the long-acting amylin analog cagrilintide with the GLP-1 agonist semaglutide (1:1). Novo Nordisk's clinical program showed greater weight loss than either component alone. Sold as a single co-lyophilized vial.
Metabolic blend pairing the triple agonist retatrutide (GIP/GLP-1/glucagon) with the amylin analog cagrilintide, described by vendors as a 'quad-pathway' stack. Investigational and unproven in humans as a combination.